Abbott Laboratories reports $12.59 billion revenue for quarter ended June 30, 2026, up 13%
Abbott Laboratories reported revenue of $12.59 billion for the quarter ended June 30, 2026, an increase of 13% from the same quarter a year earlier ($11.14 billion).
For the same period it posted net income of $928 million, down 47.8%, or $0.53 per diluted share (1.01 a year earlier).
That is a net margin of 7.4%.
On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).
Is Abbott Laboratories halal?
See the full AAOIFI screening of Abbott Laboratories
See the full AAOIFI screening of Abbott Laboratories
Source: 10-Q filed with the U.S. Securities and Exchange Commission on July 28, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.